BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37994866)

  • 1. NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?
    Filippi L; Schillaci O
    Expert Rev Anticancer Ther; 2024; 24(1-2):1-4. PubMed ID: 37994866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Study of the Radioligand 68Ga-N188 Targeting Nectin-4 for PET/CT Imaging of Advanced Urothelial Carcinoma.
    Duan X; Xia L; Zhang Z; Ren Y; Pomper MG; Rowe SP; Li X; Li N; Zhang N; Zhu H; Yang Z; Sheng X; Yang X
    Clin Cancer Res; 2023 Sep; 29(17):3395-3407. PubMed ID: 37093191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational PET Imaging of Nectin-4 Expression in Multiple Different Cancers with
    Zhang J; Duan X; Chen X; Zhang Z; Sun H; Shou J; Zhao G; Wang J; Ma Y; Yang Y; Tian X; Shen Q; Yu W; He Z; Fan Y; Yang X
    J Nucl Med; 2024 May; 65(Suppl 1):12S-18S. PubMed ID: 38719240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET Imaging of Nectin-4: A Promising Tool for Personalized/Precision Oncology.
    Jiang D; Lan X; Cai W
    Clin Cancer Res; 2023 Sep; 29(17):3259-3261. PubMed ID: 37417960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Re: First-in-Human Study of the Radioligand
    Klümper N; Eckstein M; Hölzel M; Herrmann K; Hadaschik B; Grünwald V
    Eur Urol; 2023 Nov; 84(5):514-515. PubMed ID: 37286457
    [No Abstract]   [Full Text] [Related]  

  • 6. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
    Halford Z; Anderson MK; Clark MD
    Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibody-drug conjugates directed against NECTIN-4 as a new treatment option for patients with metastatic urothelial carcinoma].
    Klümper N; Eckstein M; Kunath F; Heidegger I; Becker C; Rausch S;
    Urologie; 2023 Nov; 62(11):1193-1199. PubMed ID: 37658236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An iodine‑labelled Antibody-drug conjugate PET probe for noninvasive monitoring of Nectin-4 expression in urothelial carcinoma.
    Ren Y; Liu T; Li S; Ma X; Xia L; Wang P; Guo Q; Yao Y; Hou X; Sheng X; Zhu H; Yang Z
    Int J Pharm; 2024 Feb; 651():123756. PubMed ID: 38160990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
    Wong JL; Rosenberg JE
    Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enfortumab vedotin in the treatment of urothelial cancers and beyond.
    Wong RL; Yu EY
    Future Oncol; 2022 Sep; 18(27):3067-3084. PubMed ID: 36004667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance.
    Klümper N; Ralser DJ; Ellinger J; Roghmann F; Albrecht J; Below E; Alajati A; Sikic D; Breyer J; Bolenz C; Zengerling F; Erben P; Schwamborn K; Wirtz RM; Horn T; Nagy D; Toma M; Kristiansen G; Büttner T; Hahn O; Grünwald V; Darr C; Erne E; Rausch S; Bedke J; Schlack K; Abbas M; Zschäbitz S; Schwab C; Mustea A; Adam P; Manseck A; Wullich B; Ritter M; Hartmann A; Gschwend J; Weichert W; Erlmeier F; Hölzel M; Eckstein M
    Clin Cancer Res; 2023 Apr; 29(8):1496-1505. PubMed ID: 36534531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intertriginous erythema associated with enfortumab vedotin, a nectin-4-targeting antibody-drug conjugate, in a case with metastatic urothelial cancer: Immunohistochemical evidence for molecular-targeted eruption.
    Hasegawa T; Oyama N; Kasamatsu H; Chino T; Taga M; Hasegawa M
    J Dermatol; 2022 Dec; 49(12):e453-e454. PubMed ID: 36052729
    [No Abstract]   [Full Text] [Related]  

  • 13. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 14. Feasibility of [
    Unterrainer LM; Lindner S; Eismann L; Casuscelli J; Gildehaus FJ; Bui VN; Albert NL; Holzgreve A; Beyer L; Todica A; Brendel M; Cyran CC; Karl A; Stief CG; Ledderose ST; Unterrainer M; Bartenstein P; Wenter V; Kretschmer A
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3571-3580. PubMed ID: 35325283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
    Heath EI; Rosenberg JE
    Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Scratching the Surface: NECTIN-4 as a Surrogate for Enfortumab Vedotin Resistance.
    Aggen DH; Chu CE; Rosenberg JE
    Clin Cancer Res; 2023 Apr; 29(8):1377-1380. PubMed ID: 36749325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.
    Ghali F; Vakar-Lopez F; Roudier MP; Garcia J; Arora S; Cheng HH; Schweizer MT; Haffner MC; Lee JK; Yu EY; Grivas P; Montgomery B; Hsieh AC; Wright JL; Lam HM
    Clin Genitourin Cancer; 2023 Dec; 21(6):669-678. PubMed ID: 37344281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
    Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
    Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Dermatologic Events Associated With the Nectin-4-directed Antibody-Drug Conjugate Enfortumab Vedotin.
    Lacouture ME; Patel AB; Rosenberg JE; O'Donnell PH
    Oncologist; 2022 Mar; 27(3):e223-e232. PubMed ID: 35274723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nectin-4 is widely expressed in head and neck squamous cell carcinoma.
    Sanders C; Lau JF; Dietrich D; Strieth S; Brossart P; Kristiansen G
    Oncotarget; 2022 Oct; 13():1166-1173. PubMed ID: 36268557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.